Particle.news
Download on the App Store
5 ARTICLES
·
yesterday

Argentina Approves Lilly’s Tirzepatide for Obesity and Type 2 Diabetes, Launching in December

The first dual GIP/GLP‑1 therapy arrives through Adium distribution, offering once‑weekly prefilled pens with a reported 30% prescription discount.

El inyectable tirzepatida tiene doble acción al imitar la tarea de dos hormonas que produce de forma natural el organismo
Mounjaro, a base de tirzepatida, se presenta en el país como un inyectable semanal de doble acción hormonal para tratar obesidad y diabetes tipo 2.
Según la Organización Panamericana de la Salud, la obesidad y el sobrepeso en las Américas aumentaron del 44,4% en 1990 al 67,5% en 2022, con proyecciones de alcanzar el 73,2% en 2030. 

Overview

  • ANMAT authorization paves the way for national availability in December, with the product presented in multi‑dose KwikPen injectors under the Mounjaro brand.
  • Use is indicated for adults 18 and older with BMI of at least 30, or 27 with a related condition, and for type 2 diabetes that remains insufficiently controlled.
  • The medicine’s dual GIP/GLP‑1 mechanism is associated with weight reductions exceeding 25% and improved glycemic control in SURMOUNT and SURPASS trials.
  • Treatment is administered once weekly by subcutaneous injection in a step‑up regimen from 2.5 mg to 15 mg as an adjunct to diet and exercise, with gastrointestinal effects commonly reported.
  • Estimated retail pricing ranges from ARS 500,000 to 700,000 per monthly pen, with a 30% discount for prescriptions, and Adium handling regional commercialization except in Brazil, Mexico and Colombia.